Cisplatin chemotherapy and surgery are effective treatments for children with standard-risk hepatoblastoma but may cause considerable and irreversible hearing loss. This trial compared cisplatin with ...
Selected dose shows unprecedented disease control and overall response rates in a NSCLC clinical trial CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the ...
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced positive results from an ...
First 2 patients dosed with THIO continue to be without documented progression for 12.2 and 11.5 months and remarkably without any new anti-cancer treatment 10.2 and 8.5 months after concluding ...
Late breaking abstract to provide new updates from THIO-101 Phase 2 clinical trial in non-small cell lung cancer (NSCLC) Poster to highlight long-term therapeutic benefits of THIO sequenced with ...
THIO treatment leads to profound activation of innate and adaptive anti-tumor responses THIO depletes cancer initiating cells (CICs) and thus diminishes tumor initiation and metastasis-forming ...
IN earlier publications 1–4 we have shown possibilities of preferential inhibition of tumour growth by antimetabolites of hexose monophosphate (HMP) pathway. A number of derivatives of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback